AbbVie announced plans to acquire Immunogen and the biotech’s recently approved ADC treatment for ovarian cancer for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
Administration officials are expected to unveil the list<b> </b>before stock markets open Tuesday since it could affect public drug companies’ stock prices.
“How much is the ice cream?” A simple enough question, featured on a new TV and online advertisement, posed by a man who just wants something cold. A woman behind